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Diversa Builds a Business with Designer Bacteria
Three years ago Eric Mathur, VP of n
scientific affairs and founding part- m
ner of Diversa, a 330-person San c
Diego biotech company, went mi- w
crobe hunting in the Uzon Caldera n
in Siberia’s Kamchatka Peninsula. B
Accompanying him were two for- D
mer Soviet bioweapons scientists c
under a Department of Energy pro-
liferation-prevention program. They b
scraped up some sediment from c
an alkaline hot spring. “We isolated t
the genomes from the community D
of microorganisms residing in the n
hot springs,” Mathur recalled. “We a
chopped them up, put them in labo- l
ratory hosts, and developed com- P
plex metagenomic libraries.” The
result was Luminase, an enzyme for
bleaching paper pulp.
“Luminase enzymes enable mills
to reduce the amount of chlorine di- t
oxide (ClO2) used to bleach paper Y
pulp by up to 28%, thus reducing
tboth costs and pollution. Diversa is
targeting a quarter of the $2 billion f
pulp-chemical market. Because the zoriginal microbe was collected from
ha hot alkaline spring, Luminase can
function at high temperatures and e
at pH values in the 8–10 range. Un- —der these conditions, most enzymes
denature. Diversa released Lumi- f
nase, as well as Cottonase, an en- n
zyme for textiles, as a commercial
aproduct in 2004.
Diversa is one of a spate of com-
panies that sprang up in the last ten
years to use directed-evolution tech-
oniques to develop commercial prod-
aucts. Diversa’s bioengineered en-
azymes are precisely tailored to
mvarious industrial-process and phar-
lmaceutical applications, including
wpulp, vegetable-oil processing, ani-
smal care, aquaculture, and anti-
ainfectives. According to the Ohio
mconsultancy Freedonia Group, the
U.S. enzyme industry in 2003 was
gworth $1.2 billion.
wHealthcare Ventures, a venture-
Dcapital firm, incorporated the com-
1pany in 1992 as a sister firm to Hu-
rman Genome Sciences to develop
ntechnologies to identify and modify
tmicrobial genes with industrial po-
tential, says Martin Sabarsky, Se- dior Director, Corporate Develop- s
lent and Investor Relations. The
ompany went through a few un-
tieldy incarnations as Industrial Ge-
qome Sciences and Recombinant
tiocatalysis, Inc, but was renamed
piversa as a nod to its diverse mi-
srobial sources and applications.
iDiversa’s first products were sta-
sle Pyrolase enzymes used in se-
aondary oil and gas recovery. One
nype of Pyrolase was derived from
NA extracted from microorga-
gisms found in a hydrothermal vent,
end another version from a bug col-





The name of the game is a
Eo find the right catalyst.
sou can do this by muta-
ion, or you can do it by n
einding the perfect en-
Myme in nature. But you t
ave to do it quickly and s
hfficiently.”
vFrances H. Arnold, pro- c






Diversa’s scientists collect micro- s
rganisms in exotic locations such q
s deep-ocean vents, the arctic,
nd the digestive systems of ter- u
ites on the premise that it is a lot p
ess work to derive an enzyme that s
orks in extreme conditions if one m
tarts with microorganisms already s
dapted to living in such environ- g
ents. u
In order to legally collect microor- t
anisms abroad, Diversa works w
ithin the Convention of Biological h
iversity, a treaty ratified in 1992 by r
88 nations. Diversa must negotiate o
oyalties and access with the desig- c
ated environmental steward from i
hat country. Collections are usually u
aone by local scientists and gradtudents, although Mathur particu-
arly enjoys going on expeditions.
There are 20 types of amino acids
hat occur naturally; the specific se-
uence of amino acids determines
he nature of the protein. At Diversa,
rotein molecules are comprehen-
ively mutagenized, and the result-
ng enzymes are screened for de-
ired attributes. Sometimes all the
ttributes already exist in the origi-
al organism.
Diversa scientists identify the
ene that encodes the enzyme and
xtract that particular sequence of
NA from the organism. In a pro-
ess of recursive ensemble muta-
enesis, or “Direct Evolution,” they
utate the gene extracted from the
ost organism and transplant it into
nother vector, such as a hardy
. coli strain that is easy to grow by
tandard commercial methods.
“Earlier bioengineering compa-
ies such as Novazymes and Gen-
ncor never optimized enzymes,”
athur says. Companies reinserted
he engineered DNA back into the
ame organism to get high levels of
omologous gene expression. Di-
ersa’s innovation was to metaboli-
ally engineer the host and put the
ngineered DNA derived from the
xtremophiles into hosts that can
e grown in industrialized quanti-
ies. “By engineering the organism,
e can engineer a high level of ex-
ression for heterologous genes,”
ays Mathur, “then produce great
uantities out of it.”
The processes that the company
ses to derive its enzymes and
roducts are proprietary and expen-
ive. “With our ultra-high throughput
ethods we can process a billion
amples a day,” Mathur says. “Gi-
amatrix, our premier platform,
ses 400,000 wells per plate, using
he same footprint but a number of
ells at three orders of magnitude
igher than extant drug-company
obotics. Each microwell contains
nly 50 nl of liquid substrates.” The
ompany patented protein-engineer-
ng techniques such as Gene Site Sat-
ration Mutagenesis (GSSM), which is
library of single-point mutations,
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The optimization problem is not sim- o
hple; every enzyme usually contains
between 100 and 300 amino acids w
aand the matrix that has to be opti-
mized is N × 20, where N is the 1
pnumber of amino acids in the en-
zyme and 20 is the number of amino z
bacids available. The number of pos-
sible permutations is huge. Think on g
tthe order of 1010
6
.
Statistical methods help to re- v
aduce the number of experiments
that need to be performed. This
method is known as DOE, design of A
experiments. This algorithm was D
actually developed during WWII for m
optimizing many input/output prob- o
lems and processes. DOE is com- E
monly used in combinatorial chem- m
istry such as drug screening. Mathur f
explains that they take all 19 pos- l
sible changes for each amino acid i
and screen for phenotype improve- e
ments. Once they find the residues o
and amino acids that result in im- o
provement, they combine these mu- s
tations and screen that library for b
the best variant. “And that is how f
we get around the big, giant num- c
bers,” says Mathur. m
d
cBusiness Strategy
Diversa’s near-term revenue sources c
Aare industrial, chemical—such as
Luminase, which was commercial- s
ized within 30 months—and animal
feeds, products that have a rela- c
wtively brief development cycle of six
to nine months. These products r
aonly require the EPA to determine
whether they are toxic, as opposed t
wto more extensive FDA review. Me-
dium-term (about 5 years) but higher- f
lvalue-added products are pharma-
ceutical intermediates, such as an 3
3intermediate enzyme for Lipitor (a
registered trademark of Pfizer, Inc.) (
asynthesis. Long-term products are
small-molecule drugs and protein m
ttherapeutics such as antibodies.
But how much can Diversa dif- w
tferentiate its products? Mathur ac-
knowledged that understanding b
what the market will bear is an is-
sue. Diversa has a group of market m
oanalysts who figure out potential
market opportunities for the com- a
vpany’s products. “Our challenge is
to come out with lead candidates t
ereally quickly,” Mathur says. “In the
space of evolution, we have many m
acompetitors, but we own the spacef accessing unique methods of bi-
logical diversity.” The company
olds 200 patents. Some processes
ere patented close to 10 years
go. Because the life of a patent is
7 years, the company faces com-
etition from potential generic en-
ymes as well as enzymes derived
y other methods, and in other or-
anisms. In these brutally competi-
ive industries, innovation is only
alued when it lowers costs. “It is
ll about costs,” Mathur says.
pplications
iversa and its competitors are
aking enzymes for the production
f specific compound enantiomers.
nantiomers are isomers that are
irror images of each other and dif-
er in the way they interact with po-
arized light. Because all our biolog-
cal functions are performed by
nzymes and enzymes are enanti-
mer-specific, i.e., they can act on
ne enantiomer and not the other,
pecific chirality (the property of
eing right or left handed) is crucial
or anything that relates to biologi-
al function. For example, the L iso-
er of Thalidomide causes birth
efects, whereas the D isomer is
ompletely safe. The FDA requires
hirally pure chemicals for drugs.
nd enzymes are an exquisitely
pecific way to achieve this.
An example of an enzyme with
hiral selectivity is Nitrilase. There
ere originally nine types of bacte-
ial nitrilase in the public domain,
nd Diversa patented 237 sequences
hat the company had discovered
ith its patented approach involving
unctional screening of metagenomic
ibraries. Diversa’s nitrilases convert
-hydroxyglutaronitrile to either (S)-
-hydroxy-4-cyanobutyric acid or
R)-3-hydroxy-4-cyanobutyric acid,
precursor of Lipitor. With the un-
odified enzyme, only 89% of the to-
al 3-hydroxy-4-cyanobutyric acid
as the (R)-enantiomer. Diversa fur-
her bioengineered the enzyme to
e 99% specific.
Enzymes that are added to ani-
al feed to improve the digestibility
f certain food elements make up
nother big market. Since 2003, Di-
ersa has sold hundreds of tons of
hermally stable Phyzyme XP, an
nzyme that helps monogastric ani-
als such as hogs and chickens
bsorb phosphorus from grain, inthe U.S. alone. The product is now
waiting final approval in Europe. To-
gether with Bayer Animal Health,
Diversa recently co-developed a
fish vaccine for Salmonid Rickett-
sial Septicemia (SRS), an infection
that was destroying up to 20% of
the crop of Chilean salmon farmers.
The vaccine eliminates the need
to use antibiotics to contain the
disease.
The Future
Diversa is moving into what it terms
"metagenomics,” or how multiple
genes act in concert to perform a
task, as in a multi-step process on
an assembly line. “We are a science
moving beyond the biology of sin-
gle organisms,” says Mathur. One of
the main challenges put forth at
BIO, the biotech industry meeting
this year, was how to break down
lignin cellulose and other biomass.
Diversa is looking for the solution in
termite guts. The company is se-
quencing everything it finds there.
“We don’t know what we are look-
ing for,” says Mathur. “All organisms
have pathways to encode for small
enzymes. Microbial consortia in the
hindgut of termites are responsible
for producing the suite of enzymes
necessary for the conversion of lig-
nocellulose to fermentable sugars.”
Professor of Chemical Engineer-
ing and Biochemistry at Caltech
Frances H. Arnold was an early
consultant to the precursor to Di-
versa and rival Maxygen. “It sounds
great, but it all comes down to what
it costs,” she says. She considered
their main challenge to be targeting
the right problems, namely those
that give enzymes a chance to com-
pete. Arnold believes that the cata-
lyst-engineering technology is pow-
erful but worries that process and
engineering issues still limit many
applications.
Another issue is that the pool of
catalyst possibilities that exist in or-
ganisms that live in extreme condi-
tions is limited. “The name of the
game is to find the right catalyst,”
says Arnold. “You can do this by
mutation, or you can do it by finding
the perfect enzyme in nature. But
you have to do it quickly and effi-
ciently.”
Although all competitors say their
approaches are unique, says Ar-
nold, “In my opinion they are pretty
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in having a broad platform of ap-
proaches, solving the problem from
many different angles. This is good,
because it is not clear a priori which
approach is going to be success-
ful.”
Wendy Wolfson (wendywolfson@nasw.org)
is a freelance science writer based in Som-
erville, MA.
